

**Immunodiagnosics Market Forecast to 2030 - COVID-19 Impact and Global Analysis by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography**

Market Report | 2023-07-04 | 270 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$4550.00
- Site Price \$6550.00
- Enterprise Price \$8550.00

**Report description:**

The immunodiagnosics market size is expected to reach US\$ 34,487.80 million by 2030 from US\$ 19,218.89 million in 2022; it is estimated to record a CAGR of 7.6% from 2022 to 2030.

Immunodiagnosics is referred as a diagnostic methodology that primarily uses antigen-antibody reaction as its primary means of detection. Antibodies specific for a desired antigen can be conjugated with a radiolabel, fluorescent label, or color-forming enzyme and are used as a probe to detect it. The speed, accuracy and simplicity of such tests has led to the development of rapid techniques for the diagnosis of disease, microbes and even illegal drugs in vivo.

Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the immunodiagnosics market. Several market players are developing innovative immunodiagnostic products. For instance, Thermo Fisher Scientific has developed immunodiagnostic products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.

In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.

In April 2021, Chembio Diagnostics, Inc. launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test for use in traditional and decentralized testing settings. The rapid immunoassay test requires no instrumentation and produces results in 15 minutes.

WHO applauded the test kit developers for efforts taken to innovate and respond to the masses' requirements during the COVID-19 crisis. According to the American Society for Clinical Pathology, in March 2020, the Cepheid Xpert Xpress SARS-CoV-2 test became the first POC COVID-19 detection assay to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

Likewise, the use of immunodiagnosics in cancer treatment is increasing. In oncology, an immunodiagnostic test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the immunodiagnosics market growth.

Based on product, the immunodiagnosics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. Based on clinical indication, the market is divided into infectious diseases, Hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. By end user, the immunodiagnosics market is categorized into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. Geographically, the immunodiagnosics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), Industrial Biotechnology Leadership Forum (IBLF), International Diabetes Federation (IDF), and Ministry of Health and Prevention (MoHaP) are a few key primary and secondary sources referred to while preparing the report on the immunodiagnosics market.

Based on product, the immunodiagnosics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest immunodiagnosics market share in 2022. The chemiluminescence immunoassays (CLIA) segment is anticipated to record a significant growth rate during the forecast period. Enzyme-linked immunosorbent assay (ELISA) frequently measures antibodies, proteins, antigens, and glycoproteins in biological samples. ELISA is used for HIV diagnosis, pregnancy tests, and cytokine or soluble receptor measurement (from cell supernatant or serum). It has replaced

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

radioimmunoassay (RIA) to become one of the most common and reliable diagnostic tools. Moreover, the ELISA technique advancement led to the development of quantitative PCR, fluorogenic, and electro-chemiluminescent reporters to generate signals. Further, ELISA, along with lateral flow immunoassays, was widely used during the COVID-19 pandemic to identify individuals having antibodies developed against SARS-CoV-2, thus driving the immunodiagnosics market growth.

## Immunodiagnosics Market: Competitive Landscape and Key Developments

Abbott Laboratories, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Danaher Corp, Thermo Fisher Scientific Inc, PerkinElmer Inc, Shenzhen Mindray Bio-Medical Electronics Co Ltd, bioMerieux SA, Svar Life Science AB, and Siemens Healthineers AG are a few key companies operating in the immunodiagnosics market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.

A few of the recent developments in the global immunodiagnosics market are mentioned below:

- In May 2023, Thermo Fisher Scientific announced that the US FDA had cleared its immunoassays, B<sub>2</sub>MIG plus KRYPTOR and B<sub>2</sub>MIG sFit-1 KRYPTOR novel biomarkers. These immunoassays assess risks and clinical management of preeclampsia, a severe pregnancy complication.

- In April 2023, Thermo Fisher Scientific announced a partnership with ALPCO-GeneProof, a global leader in diagnostics. The partnership has helped to bring TaqPath Menu | GeneProof PCR kits into the market.

- In July 2022, Abbott Diagnostics announced its participation in American Association for Clinical Chemistry (AACC) 2022. In the exhibition, the company demonstrated its diagnostics systems and analyzers.

- In May 2022, Roche and The Global Fund to Fight AIDS, Tuberculosis and Malaria joined forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB).

- In September 2022, Mindray launched the ToRCH Panel. With this panel, the company offers high-quality assays to meet different clinical needs. Mindray ToRCH kits support diverse sample types with less quality controls and sample volumes, which ensures great ease and convenience during clinical detection.

- In May 2022, Thermo Fisher Scientific announced that the Phadia 2500+ series of instruments are available for autoimmune testing in the US. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

- In July 2022, Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The Elecsys HCV Duo immunoassay enables a significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.

## Table of Contents:

### TABLE OF CONTENTS

1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.3 Market Segmentation
  - 1.3.1 Global Immunodiagnosics Market - by Product
  - 1.3.2 Global Immunodiagnosics Market - by Clinical Indication
  - 1.3.3 Global Immunodiagnosics Market - by End User
  - 1.3.4 Global Immunodiagnosics Market - by Geography
- 2. Immunodiagnosics Market - Key Takeaways
- 3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
- 4. Immunodiagnosics Market - Market Landscape
  - 4.1 Overview
  - 4.2 PEST Analysis
    - 4.2.1 North America PEST Analysis
    - 4.2.2 Europe PEST Analysis
    - 4.2.3 Asia Pacific PEST Analysis
    - 4.2.5 Middle East & Africa PEST Analysis
    - 4.2.6 South & Central America PEST Analysis
  - 4.3 Expert's Opinion
- 5. Immunodiagnosics Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Increasing Prevalence of Infectious Diseases
    - 5.1.2 Growing Use of Point-of-Care Immunodiagnosics
  - 5.2 Market Restraints
    - 5.2.1 Inadequate Reimbursement Scenario
  - 5.3 Market Opportunities
    - 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
  - 5.4 Future Trends
    - 5.4.1 Technological Advancements in Immunodiagnosics
  - 5.5 Impact Analysis
- 6. Immunodiagnosics Market - Global Analysis
  - 6.1 Global Immunodiagnosics Market Revenue Forecast and Analysis
  - 6.2 Global Immunodiagnosics Market, by Geography - Forecast and Analysis
  - 6.3 Market Positioning of Key Players
- 7. Immunodiagnosics Market Analysis - by Product
  - 7.1 Overview
  - 7.2 Immunodiagnosics Market, By Product, 2022 & 2030 (%)
    - 7.3 Enzyme-linked Immunosorbent Assays (ELISA)
      - 7.3.1 Overview
      - 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
    - 7.4 Chemiluminescence Immunoassays (CLIA)
      - 7.4.1 Overview
      - 7.4.2 Chemiluminescence Immunoassays (CLIA): Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
        - 7.4.3 Vitamin D Assay
          - 7.4.3.1 Overview
          - 7.4.3.2 Vitamin D Assay: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
        - 7.4.4 HIV Detection

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.4.1 Overview
- 7.4.4.2 HIV Detection: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 7.4.5 HIV Ag/Ab Combo assay
- 7.4.5.1 Overview
- 7.4.5.2 HIV Ag/Ab Combo Assay: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 7.4.6 Other Tests
- 7.4.6.1 Overview
- 7.4.6.2 Other Tests: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 7.5 Radioimmunoassays (RIA)
- 7.5.1 Overview
- 7.5.2 Radioimmunoassays (RIA): Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8. Immunodiagnosics Market Analysis - Clinical Indication
- 8.1 Overview
- 8.2 Global Immunodiagnosics Market Share by Clinical Indication - 2022 & 2030 (%)
- 8.3 Infectious Diseases:
- 8.3.1 Overview
- 8.3.2 Infectious Diseases: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.1 COVID-19
- 8.3.2.1.1 Overview
- 8.3.2.1.2 COVID-19: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.2 Tuberculosis
- 8.3.2.2.1 Overview
- 8.3.2.2.2 Tuberculosis: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.3 Lyme
- 8.3.2.3.1 Overview
- 8.3.2.3.2 Lyme: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.4 Infection Management
- 8.3.2.4.1 Overview
- 8.3.2.4.2 Infection Management: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.5 Zika
- 8.3.2.5.1 Overview
- 8.3.2.5.2 Zika: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.6 Treponema
- 8.3.2.6.1 Overview
- 8.3.2.6.2 Treponema: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.7 TORCH
- 8.3.2.7.1 Overview
- 8.3.2.7.2 TORCH: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.8 Measles and Mumps
- 8.3.2.8.1 Overview
- 8.3.2.8.2 Measles and Mumps: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.3.2.9 VZV
- 8.3.2.9.1 Overview
- 8.3.2.9.2 VZV: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.3.2.10 EBV
  - 8.3.2.10.1 Overview
  - 8.3.2.10.2 EBV: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.4 Hepatitis+HIV:
  - 8.4.1 Overview
  - 8.4.2 Hepatitis+HIV: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.5 Gastrointestinal
  - 8.5.1 Overview
  - 8.5.2 Gastrointestinal: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.6 Metabolic Disorders
  - 8.6.1 Overview
  - 8.6.2 Metabolics: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.7 Endocrinology
  - 8.7.1 Overview
  - 8.7.2 Endocrinology: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 8.7.3 Hypertension
    - 8.7.3.1 Overview
    - 8.7.3.2 Hypertension: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 8.7.4 Growth
    - 8.7.4.1 Overview
    - 8.7.4.2 Growth: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 8.7.5 Diabetes
    - 8.7.5.1 Overview
    - 8.7.5.2 Diabetes: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 8.7.6 Thyroid
    - 8.7.6.1 Overview
    - 8.7.6.2 Thyroid: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 8.7.7 Reproductive Endocrinology
    - 8.7.7.1 Overview
    - 8.7.7.2 Reproductive Endocrinology: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 8.8 Others
  - 8.8.1 Overview
  - 8.8.2 Others: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 9. Immunodiagnosics Market Analysis - End User
  - 9.1 Overview
  - 9.2 Global Immunodiagnosics Market Share by End User - 2022 & 2030 (%)
  - 9.3 Hospitals
    - 9.3.1 Overview
    - 9.3.2 Hospitals: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.4 Clinics
    - 9.4.1 Overview
    - 9.4.2 Clinics: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.5 Diagnostic Laboratories
    - 9.5.1 Overview
    - 9.5.2 Diagnostic Laboratories: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
  - 9.6 Academic and Research Institutes
    - 9.6.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.6.2 Academic and Research Institutes: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 9.7 Others
  - 9.7.1 Overview
  - 9.7.2 Others: Immunodiagnosics Market Revenue and Forecast to 2030 (US\$ Million)
- 10. Immunodiagnosics Market - Revenue and Forecast to 2030 - Geographic Analysis
  - 10.1 North America: Immunodiagnosics Market
    - 10.1.1 Overview
    - 10.1.2 North America: Immunodiagnosics Market - Revenue and Forecast to 2028 (US\$ Million)
    - 10.1.3 North America: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
      - 10.1.3.1 North America: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
    - 10.1.4 North America: Immunodiagnosics Market, by Clinical Indication - 2020-2030 (US\$ Million)
      - 10.1.4.1 North America: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
      - 10.1.4.2 North America: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
    - 10.1.5 North America: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
      - 10.1.5.1 US: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
        - 10.1.5.1.1 Overview
        - 10.1.5.1.2 US: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
        - 10.1.5.1.3 US: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
          - 10.1.5.1.3.1 US: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
          - 10.1.5.1.4 US: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
            - 10.1.5.1.4.1 US: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
            - 10.1.5.1.4.2 US: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
          - 10.1.5.1.5 US: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
        - 10.1.5.2 Canada: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
          - 10.1.5.2.1 Overview
          - 10.1.5.2.2 Canada: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
          - 10.1.5.2.3 Canada: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
            - 10.1.5.2.3.1 Canada: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
            - 10.1.5.2.4 Canada: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
              - 10.1.5.2.4.1 Canada: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
              - 10.1.5.2.4.2 Canada: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
            - 10.1.5.2.5 Canada: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
          - 10.1.5.3 Mexico: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
            - 10.1.5.3.1 Overview
            - 10.1.5.3.2 Mexico: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
            - 10.1.5.3.3 Mexico: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
              - 10.1.5.3.3.1 Mexico: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
              - 10.1.5.3.4 Mexico: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
                - 10.1.5.3.4.1 Mexico: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
                - 10.1.5.3.4.2 Mexico: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
              - 10.1.5.3.5 Mexico: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
        - 10.2 Europe: Immunodiagnosics Market
          - 10.2.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.2.2 Europe: Immunodiagnosics Market - Revenue and Forecast to 2028 (US\$ Million)
- 10.2.3 Europe: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
  - 10.2.3.1 Europe: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
- 10.2.4 Europe: Immunodiagnosics Market, by Clinical Indication - 2020-2030 (US\$ Million)
  - 10.2.4.1 Europe: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
  - 10.2.4.2 Europe: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
- 10.2.5 Europe: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
  - 10.2.5.1 UK: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
    - 10.2.5.1.1 Overview
    - 10.2.5.1.2 UK: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
      - 10.2.5.1.3 UK: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
        - 10.2.5.1.3.1 UK: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
        - 10.2.5.1.4 UK: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
          - 10.2.5.1.4.1 UK: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
            - 10.2.5.1.4.2 UK: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
          - 10.2.5.1.5 UK: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
      - 10.2.5.2 Germany: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
        - 10.2.5.2.1 Overview
        - 10.2.5.2.2 Germany: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
          - 10.2.5.2.3 Germany: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
            - 10.2.5.2.3.1 Germany: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
            - 10.2.5.2.4 Germany: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
              - 10.2.5.2.4.1 Germany: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
                - 10.2.5.2.4.2 Germany: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
              - 10.2.5.2.5 Germany: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
        - 10.2.5.3 France: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
          - 10.2.5.3.1 Overview
          - 10.2.5.3.2 France: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
            - 10.2.5.3.3 France: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
              - 10.2.5.3.3.1 France: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
              - 10.2.5.3.4 France: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
                - 10.2.5.3.4.1 France: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
                  - 10.2.5.3.4.2 France: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
                - 10.2.5.3.5 France: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
          - 10.2.5.4 Italy: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
            - 10.2.5.4.1 Overview
            - 10.2.5.4.2 Italy: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
              - 10.2.5.4.3 Italy: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
                - 10.2.5.4.3.1 Italy: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
                - 10.2.5.4.4 Italy: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
                  - 10.2.5.4.4.1 Italy: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
                    - 10.2.5.4.4.2 Italy: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.5.4.5 Italy: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.2.5.5 Spain: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
  - 10.2.5.5.1 Overview
  - 10.2.5.5.2 Spain: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
  - 10.2.5.5.3 Spain: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
    - 10.2.5.5.3.1 Spain: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
    - 10.2.5.5.4 Spain: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
      - 10.2.5.5.4.1 Spain: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
      - 10.2.5.5.4.2 Spain: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
    - 10.2.5.5.5 Spain: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
  - 10.2.5.6 Rest of Europe: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
    - 10.2.5.6.1 Overview
    - 10.2.5.6.2 Rest of Europe: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
    - 10.2.5.6.3 Rest of Europe: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
      - 10.2.5.6.3.1 Rest of Europe: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
      - 10.2.5.6.4 Rest of Europe: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
        - 10.2.5.6.4.1 Rest of Europe: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
        - 10.2.5.6.4.2 Rest of Europe: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
      - 10.2.5.6.5 Rest of Europe: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
  - 10.3 Asia Pacific: Immunodiagnosics Market
    - 10.3.1 Overview
    - 10.3.2 Asia Pacific: Immunodiagnosics Market - Revenue and Forecast to 2028 (US\$ Million)
    - 10.3.3 Asia Pacific: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
      - 10.3.3.1 Asia Pacific: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
      - 10.3.4 Asia Pacific: Immunodiagnosics Market, by Clinical Indication - 2020-2030 (US\$ Million)
        - 10.3.4.1 Asia Pacific: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
        - 10.3.4.2 Asia Pacific: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
      - 10.3.5 Asia Pacific: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
        - 10.3.5.1 China: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
          - 10.3.5.1.1 Overview
          - 10.3.5.1.2 China: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
          - 10.3.5.1.3 China: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
            - 10.3.5.1.3.1 China: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
            - 10.3.5.1.4 China: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
              - 10.3.5.1.4.1 China: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
              - 10.3.5.1.4.2 China: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
            - 10.3.5.1.5 China: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
          - 10.3.5.2 Japan: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
            - 10.3.5.2.1 Overview
            - 10.3.5.2.2 Japan: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
            - 10.3.5.2.3 Japan: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
              - 10.3.5.2.3.1 Japan: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.5.2.4 Japan: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.2.4.1 Japan: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.2.4.2 Japan: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.2.5 Japan: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.3.5.3 India: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.3.1 Overview
- 10.3.5.3.2 India: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.3.3 India: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
- 10.3.5.3.3.1 India: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.3.4 India: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.3.4.1 India: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.3.4.2 India: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.3.5 India: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.3.5.4 Australia: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.4.1 Overview
- 10.3.5.4.2 Australia: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.4.3 Australia: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
- 10.3.5.4.3.1 Australia: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.4.4 Australia: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.4.4.1 Australia: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.4.4.2 Australia: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.4.5 Australia: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.3.5.5 South Korea: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.5.1 Overview
- 10.3.5.5.2 South Korea: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.5.3 South Korea: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
- 10.3.5.5.3.1 South Korea: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.5.4 South Korea: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.5.4.1 South Korea: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.5.4.2 South Korea: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.5.5 South Korea: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.3.5.6 Rest of Asia Pacific: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.6.1 Overview
- 10.3.5.6.2 Rest of Asia Pacific: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.6.3 Rest of Asia Pacific: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)
- 10.3.5.6.3.1 Rest of Asia Pacific: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.6.4 Rest of Asia Pacific: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.6.4.1 Rest of Asia Pacific: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.6.4.2 Rest of Asia Pacific: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)
- 10.3.5.6.5 Rest of Asia Pacific: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)
- 10.4 Middle East & Africa: Immunodiagnosics Market
- 10.4.1 Overview
- 10.4.2 Middle East & Africa: Immunodiagnosics Market - Revenue and Forecast to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.4.3 Middle East & Africa: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.4.3.1 Middle East & Africa: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.4.4 Middle East & Africa: Immunodiagnosics Market, by Clinical Indication - 2020-2030 (US\$ Million)

10.4.4.1 Middle East & Africa: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.4.4.2 Middle East & Africa: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.4.5 Middle East & Africa: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.4.5.1 UAE: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.1.1 Overview

10.4.5.1.2 UAE: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.1.3 UAE: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.4.5.1.3.1 UAE: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.4.5.1.4 UAE: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.1.4.1 UAE: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.1.4.2 UAE: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.1.5 UAE: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.4.5.2 Saudi Arabia: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.2.1 Overview

10.4.5.2.2 Saudi Arabia: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.2.3 Saudi Arabia: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.4.5.2.3.1 Saudi Arabia: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.4.5.2.4 Saudi Arabia: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.2.4.1 Saudi Arabia: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.2.4.2 Saudi Arabia: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.2.5 Saudi Arabia: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.4.5.3 South Africa: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.3.1 Overview

10.4.5.3.2 South Africa: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.3.3 South Africa: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.4.5.3.3.1 South Africa: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.4.5.3.4 South Africa: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.3.4.1 South Africa: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.3.4.2 South Africa: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.3.5 South Africa: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.4.5.4 Rest of Middle East & Africa: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.4.1 Overview

10.4.5.4.2 Rest of Middle East & Africa: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.4.3 Rest of Middle East & Africa: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.4.5.4.3.1 Rest of Middle East & Africa: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.4.5.4.4 Rest of Middle East & Africa: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.4.4.1 Rest of Middle East & Africa: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

10.4.5.4.2 Rest of Middle East & Africa: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.4.5.4.5 Rest of Middle East & Africa: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.5 South & Central America: Immunodiagnosics Market

10.5.1 Overview

10.5.2 South & Central America: Immunodiagnosics Market - Revenue and Forecast to 2028 (US\$ Million)

10.5.3 South & Central America: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.5.3.1 South & Central America: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.5.4 South & Central America: Immunodiagnosics Market, by Clinical Indication - 2020-2030 (US\$ Million)

10.5.4.1 South & Central America: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.5.4.2 South & Central America: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.5.5 South & Central America: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.5.5.1 Brazil: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.1.1 Overview

10.5.5.1.2 Brazil: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.1.3 Brazil: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.5.5.1.3.1 Brazil: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.5.5.1.4 Brazil: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.1.4.1 Brazil: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.1.4.2 Brazil: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.1.5 Brazil: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.5.5.2 Argentina: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.2.1 Overview

10.5.5.2.2 Argentina: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.2.3 Argentina: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.5.5.2.3.1 Argentina: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.5.5.2.4 Argentina: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.2.4.1 Argentina: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.2.4.2 Argentina: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.2.5 Argentina: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

10.5.5.3 Rest of South & Central America: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.3.1 Overview

10.5.5.3.2 Rest of South & Central America: Immunodiagnosics Market - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.3.3 Rest of South & Central America: Immunodiagnosics Market, by Product, 2020-2030 (US\$ Million)

10.5.5.3.3.1 Rest of South & Central America: Immunodiagnosics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.5.5.3.4 Rest of South & Central America: Immunodiagnosics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.3.4.1 Rest of South & Central America: Immunodiagnosics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.3.4.2 Rest of South & Central America: Immunodiagnosics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.5.5.3.5 Rest of South & Central America: Immunodiagnosics Market, by End User, 2020-2030 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11. Impact Of COVID-19 Pandemic on Immunodiagnostics Market
  - 11.1 North America: Impact Assessment of COVID-19 Pandemic
  - 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  - 11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  - 11.4 South & Central America: Impact Assessment of COVID-19 Pandemic
  - 11.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
- 12. Global Immunodiagnostics Market -Industry Landscape
  - 12.1 Overview
  - 12.2 Growth Strategies in the Immunodiagnostics Market
  - 12.3 Inorganic Growth Strategies
    - 12.3.1 Overview
  - 12.4 Organic Growth Strategies
    - 12.4.1 Overview
- 13. Company Profiles
  - 13.1 Abbott Laboratories
    - 13.1.1 Key Facts
    - 13.1.2 Business Description
    - 13.1.3 Products and Services
    - 13.1.4 Financial Overview
    - 13.1.5 SWOT Analysis
    - 13.1.6 Key Developments
  - 13.2 F. Hoffmann-La Roche Ltd
    - 13.2.1 Key Facts
    - 13.2.2 Business Description
    - 13.2.3 Products and Services
    - 13.2.4 Financial Overview
    - 13.2.5 SWOT Analysis
    - 13.2.6 Key Developments
  - 13.3 DiaSorin SpA
    - 13.3.1 Key Facts
    - 13.3.2 Business Description
    - 13.3.3 Products and Services
    - 13.3.4 Financial Overview
    - 13.3.5 SWOT Analysis
    - 13.3.6 Key Developments
  - 13.4 Danaher Corp
    - 13.4.1 Key Facts
    - 13.4.2 Business Description
    - 13.4.3 Products and Services
    - 13.4.4 Financial Overview
    - 13.4.5 SWOT Analysis
    - 13.4.6 Key Developments
  - 13.5 Thermo Fisher Scientific Inc
    - 13.5.1 Key Facts
    - 13.5.2 Business Description
    - 13.5.3 Products and Services
    - 13.5.4 Financial Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 PerkinElmer Inc
  - 13.6.1 Key Facts
  - 13.6.2 Business Description
  - 13.6.3 Products and Services
  - 13.6.4 Financial Overview
  - 13.6.5 SWOT Analysis
  - 13.6.6 Key Developments
- 13.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  - 13.7.1 Key Facts
  - 13.7.2 Business Description
  - 13.7.3 Products and Services
  - 13.7.4 Financial Overview
  - 13.7.5 SWOT Analysis
  - 13.7.6 Key Developments
- 13.8 bioMerieux SA
  - 13.8.1 Key Facts
  - 13.8.2 Business Description
  - 13.8.3 Products and Services
  - 13.8.4 Financial Overview
  - 13.8.5 SWOT Analysis
  - 13.8.6 Key Developments
- 13.9 Svar Life Science AB
  - 13.9.1 Key Facts
  - 13.9.2 Business Description
  - 13.9.3 Products and Services
  - 13.9.4 Financial Overview
  - 13.9.5 SWOT Analysis
  - 13.9.6 Key Developments
- 13.10 Siemens Healthcare GmbH
  - 13.10.1 Key Facts
  - 13.10.2 Business Description
  - 13.10.3 Products and Services
  - 13.10.4 Financial Overview
  - 13.10.5 SWOT Analysis
  - 13.10.6 Key Developments
- 14. Appendix
  - 14.1 About The Insight Partners
  - 14.2 Glossary of Terms

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Immunodiagnosics Market Forecast to 2030 - COVID-19 Impact and Global Analysis by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography**

Market Report | 2023-07-04 | 270 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License           | Price     |
|----------------|-------------------|-----------|
|                | Single User Price | \$4550.00 |
|                | Site Price        | \$6550.00 |
|                | Enterprise Price  | \$8550.00 |
|                |                   | VAT       |
|                |                   | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|             |                      |            |                      |
|-------------|----------------------|------------|----------------------|
| Email*      | <input type="text"/> | Phone*     | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title*  | <input type="text"/> |            |                      |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2026-06-09"/> |
|               |                      | Signature                     | <input type="text"/>                    |